Boehringer Ingelheim demonstrates the long-term commitment for animal well-being by supporting these biennial awards- The winner in each of the two awards will receive 10,000 euro ($10,696.50 USD)
The biennial Ruminant Well-Being Awards, held in partnership with the World Association for Buiatrics (WAB), reflects Boehringer Ingelheim’s long-term commitment to promoting the health and well-being of farm animals. The event, sponsored exclusively by Boehringer Ingelheim, is held at the annual World Buiatrics Congress highlighting the important role played by vets in the continuous improvement of animal welfare for food-producing ruminants.
The next congress will be held in Madrid, Spain (September 27 to October 1, 2020), and applications will be open for two different awards:
(1) Ruminant Well-Being Research Award, and
(2) Ruminant Well-Being Achievement Award.
Each award comprises a 10,000 euro ($10,696.50 USD)-prize for each winner, plus reimbursement of the recipient’s travel expenses to attend the conference and the ceremony.
The Ruminant Well-Being Research Award
This award will be granted to a recent PhD graduate in veterinary science, animal science or related disciplines that made an exceptional contribution to the scientific knowledge on ruminant well-being achieving some of the following:
- Improving the understanding of pain expression as well as the recognition of pain and other forms of suffering
- Developing scientific methods of measuring animal well-being, with potential practical applications
- Developing scientific based strategies that improve animal well-being
- Identifying issues of concern and seeking solutions to challenges
- Developing methods to change human attitudes and behavior to ensure proper stewardship
The Ruminant Well-Being Achievement Award
The second award category will be granted to a practicing veterinarian or a researcher in veterinary science, animal science or related disciplines to recognize his/her achievements in advancing the well-being of ruminants. It aims at rewarding an individual that made contribution to the well-being of food-producing ruminants by achieving some of the following:
- Improving the understanding of pain expression as well as the recognition of pain and other forms of suffering
- Developing scientific methods of measuring animal well-being
- Developing practical well-being assessment methods
- Developing practical strategies to improve animal well-being
- Raising awareness of issues of concern; engaging different stakeholders in seeking solutions to challenges
- Changing human attitudes and behavior to ensure proper stewardship
- Communicating information about, and proposing solutions to, animal well-being challenges with courage and integrity
The winner of the award will be selected by an independent expert panel under the supervision of Xavier Manteca, Professor in Applied Ethology at the University of Barcelona and founder of the Farm Animal Welfare Education Centre (www.fawec.org).
Applications will be accepted until April 30, 2020. Application forms and criteria can be found on the Boehringer Ingelheim website on Farm Animal Well-Being www.farmanimalwellbeing.com.
Our pledge
Science shows that when farm animals are not just healthy, but also free of pain and discomfort, there are far-reaching positive consequences. At Boehringer Ingelheim, we believe that vets play a key role in promoting better farming practices. Our aim is to build and share scientific knowledge around farm animal well-being, where effective pain management benefits livestock and rewards farmers, while satisfying the social demands for responsible farming. Because farm animal well-being works.
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. The company has pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and aims to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
